J84.02

Clinical Causes: Genetic mutations affecting the SLC34A2 gene, which encodes a sodium-phosphate cotransporter essential for phosphate transport in alveolar cells

Key Symptoms: Shortness of breath, especially during exertion Chronic dry cough Chest discomfort or tightness Fatigue In some cases, patients remain asymptomatic for years

Diagnosis Path: Diagnosis of pulmonary alveolar microlithiasis involves several specialized tests and imaging studies: - **Chest X-ray:** Typically reveals a diffuse, sand-like or nodular pattern throughout both lungs, often described as a 'sandstorm' appearance. - **High-resolution computed tomography (HRCT):** Provides detailed images showing calcified nodules within alveoli, helping to distinguish PAM from other lung diseases. - **Lung biopsy:** In certain cases, a tissue sample analyzed under a microscope confirms the presence of microliths within alveolar spaces. - **Genetic testing:** Identifies mutations in the SLC34A2 gene, supporting the diagnosis. Early detection is challenging due to the often subtle symptoms and the rarity of the condition.

Treatment Protocols: Currently, there is no definitive cure for pulmonary alveolar microlithiasis. Management strategies focus on relieving symptoms and monitoring disease progression: - **Supportive care:** Includes oxygen therapy for patients with significant respiratory impairment. - **Medication:** No specific medications are proven effective; however, some therapies like corticosteroids or calcium chelators have been tried with limited success. - **Lung transplantation:** Considered in advanced cases where lung function is severely compromised. - **Regular follow-up:** Monitoring pulmonary function and imaging studies are important for tracking disease progression. Research continues to explore potential new treatments targeting the pathophysiology of PAM.